drugset / Trial / NCT01206881
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
Phase 2
Completed
45 enrolled
Herlev Hospital
Aarhus University Hospital · collabOdense University Hospital · collabRigshospitalet, Denmark · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of neoadjuvant treatment with pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide +/- trastuzumab followed by docetaxel in patients with locally advanced, inflammatory breast cancer or with a primary tumor \> 5 cm.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-05
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | 35 mg/m2 | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | — |